158 related articles for article (PubMed ID: 14520596)
1. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
Geiss HC; Dietlein M; Parhofer KG
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):322-4. PubMed ID: 14520596
[TBL] [Abstract][Full Text] [Related]
2. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
Sposito AC; Mansur AP; Maranhão RC; Rodrigues-Sobrinho CR; Coelho OR; Ramires JA
Braz J Med Biol Res; 2001 Feb; 34(2):177-82. PubMed ID: 11175492
[TBL] [Abstract][Full Text] [Related]
3. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
Virgolini I; Koller E; Li S; Yang Q; Banyai M; Rauscha F; Pidlich J; Pirker W; Sinzinger H
Atherosclerosis; 1993 Sep; 102(2):217-26. PubMed ID: 8251008
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
5. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
Hernández-Mijares A; Lluch I; Vizcarra E; Martínez-Triguero ML; Ascaso JF; Carmena R
Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
[TBL] [Abstract][Full Text] [Related]
6. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
Lang PD; Vollmar J
Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
[No Abstract] [Full Text] [Related]
7. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
[TBL] [Abstract][Full Text] [Related]
8. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
9. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels.
Halle M; Berg A; Baumstark MW; König D; Huonker M; Keul Joseph
Atherosclerosis; 1999 Mar; 143(1):185-92. PubMed ID: 10208494
[TBL] [Abstract][Full Text] [Related]
10. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
[TBL] [Abstract][Full Text] [Related]
11. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Chapman MJ; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
[TBL] [Abstract][Full Text] [Related]
12. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
13. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
14. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
Geiss HC; Otto C; Schwandt P; Parhofer KG
Metabolism; 2001 Aug; 50(8):983-8. PubMed ID: 11474489
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
Wolf HR
Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
[TBL] [Abstract][Full Text] [Related]
16. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
17. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Bruckert E; Dejager S; Chapman MJ
Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
[TBL] [Abstract][Full Text] [Related]
19. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
[TBL] [Abstract][Full Text] [Related]
20. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
